CD22 and acute lymphoblastic leukemia: Subsequent therapy including CD19/CD22-directed CAR-T cells and second allo-HSCT failed to prevent CD19-positive BCP-ALL relapse, although an unclassifiable subpopulation of leukemic cells was successfully eliminated from the BM (Figure S1).